BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This radiolabeled formulation features iodine-131 labeled dimeric cyclic arginine-glycine-aspartic acid modified liposomes (131I-labeled c(RGD)2-modified liposomes) engineered as a high-sensitivity radiotracer tracking model with enhanced surface affinity. The internal matrix incorporates the radioactive halogen isotope iodine-131 (131I) covalently bound to lipid anchors within a high-purity lipid bilayer functionalized with surface-bound dimeric cyclic arginine-glycine-aspartic acid [c(RGD)2] peptide units. This specific structural arrangement prevents the premature environmental dissociation of the radiolabeled tracer and provides a stable, highly tracking-sensitive liposomal framework. The resulting vesicles exhibit a narrow size distribution profile and high colloidal stability for radiometric mass transport calibrations.
Source
Custom synthesis
Functional Group
c(RGD)2 peptide
Form
Solid or powder
Purity
≥95%
Impurities
No visible impurities to the naked eye.
Identity
HPLC/MS/NMR
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.